Biotech Analyst Minter, along with Dr. Maski of Boston Children’s Hospital and Dr. Scammell, Neurology Professor at Beth Israel Deaconess Medical Center, discuss the development landscape for sleep disorders, including narcolepsy, with Axsome’s pivotal SYMPHONY trial of AXS-12 (reboxetine) ongoing and expected to complete enrollment in 3Q2023 on an Analyst/Industry conference call to be held on July 14 at 10 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- William Blair biotech analyst to hold an analyst/industry conference call
- Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
- Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
- Axsome Therapeutics initiates FOCUS Phase 3 trial of solriamfetol in ADHD
- Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock